N J Chao

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Blazing a new TRAIL in hematopoietic cell transplantation
    Nelson Chao
    Duke University Medical Center, Bone Marrow Transplant Program, Durham, North Carolina 27710, USA
    J Clin Invest 123:2362-3. 2013
  2. ncbi request reprint Minors come of age: Minor histocompatibility antigens and graft-versus-host disease
    Nelson J Chao
    Department of Medicine and Immunology, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:215-23. 2004
  3. ncbi request reprint Accidental or intentional exposure to ionizing radiation: biodosimetry and treatment options
    Nelson J Chao
    Duke University, Durham, NC 27710, USA
    Exp Hematol 35:24-7. 2007
  4. ncbi request reprint Prophylaxis and treatment of acute graft-versus-host disease
    Nelson J Chao
    Division of Cellular Therapy Bone Marrow Transplantation, Department of Medicine and Immunology, Duke University Medical Center, Durham, NC 27705, USA
    Semin Hematol 43:32-41. 2006
  5. ncbi request reprint Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial
    N J Chao
    Duke University, Durham, North Carolina, USA
    Biol Blood Marrow Transplant 6:254-61. 2000
  6. ncbi request reprint Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:569-75. 2004
  7. ncbi request reprint Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells
    Nelson J Chao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 8:249-56. 2002
  8. ncbi request reprint A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Clin Cancer Res 5:3411-8. 1999
  9. pmc Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
    D A Rizzieri
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 43:327-33. 2009
  10. ncbi request reprint A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant
    Y Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Clin Cancer Res 5:3425-31. 1999

Research Grants

  1. Novel Approaches to Stem Cell Transplantation
    Nelson Chao; Fiscal Year: 2007
  2. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2007
  3. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2006
  4. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2003
  5. CORD BLOOD TRANSPLANTATION IN ADULT RECIPIENTS
    Nelson Chao; Fiscal Year: 2001

Detail Information

Publications82

  1. pmc Blazing a new TRAIL in hematopoietic cell transplantation
    Nelson Chao
    Duke University Medical Center, Bone Marrow Transplant Program, Durham, North Carolina 27710, USA
    J Clin Invest 123:2362-3. 2013
    ..In this issue of the JCI, Ghosh et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: balancing the beneficial antitumor effect with the harmful anti-host effect...
  2. ncbi request reprint Minors come of age: Minor histocompatibility antigens and graft-versus-host disease
    Nelson J Chao
    Department of Medicine and Immunology, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:215-23. 2004
    ..Alternatively, these miHA could be exploited as targets for a more potent graft-versus-malignancy effect. This area of miHA promises to continue to be an exciting area of continued research...
  3. ncbi request reprint Accidental or intentional exposure to ionizing radiation: biodosimetry and treatment options
    Nelson J Chao
    Duke University, Durham, NC 27710, USA
    Exp Hematol 35:24-7. 2007
    ..Our ability to understand and rapidly obtain data on the absorbed dose and have access to radiation mitigators are of critical importance if we are to have a beneficial impact in the exposed population...
  4. ncbi request reprint Prophylaxis and treatment of acute graft-versus-host disease
    Nelson J Chao
    Division of Cellular Therapy Bone Marrow Transplantation, Department of Medicine and Immunology, Duke University Medical Center, Durham, NC 27705, USA
    Semin Hematol 43:32-41. 2006
    ..Better understanding of the allogeneic response that is responsible for GVHD will facilitate the development of such an approach...
  5. ncbi request reprint Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial
    N J Chao
    Duke University, Durham, North Carolina, USA
    Biol Blood Marrow Transplant 6:254-61. 2000
    ....
  6. ncbi request reprint Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:569-75. 2004
    ..This result provides a basis for further exploring this potentially curative approach to selected patients who lack matched related or unrelated hematopoietic stem cell donors...
  7. ncbi request reprint Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells
    Nelson J Chao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 8:249-56. 2002
    ..Moreover, the presence of TREC-positive cells within 1 year suggests that thymic recovery is likewise accelerated in non myeloablative compared to myeloablative regimens...
  8. ncbi request reprint A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Clin Cancer Res 5:3411-8. 1999
    ..G-CSF administration after each PBPC infusion appears to accelerate time to neutrophil recovery but does not affect red cell or platelet engraftment...
  9. pmc Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
    D A Rizzieri
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 43:327-33. 2009
    ..However, long-term survival still remains poor, primarily because of relapse in these patients...
  10. ncbi request reprint A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant
    Y Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Clin Cancer Res 5:3425-31. 1999
    ..This model can identify two subgroups of HRPBC patients with low (12%) and high (65%) risk for recurrence after HDCT. Future research that tests new therapies will focus on those patients with a high score...
  11. ncbi request reprint Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Biol Blood Marrow Transplant 6:58-69. 2000
    ....
  12. ncbi request reprint Acute graft-vs-host disease: pathobiology and management
    H Goker
    Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC 27705, USA
    Exp Hematol 29:259-77. 2001
    ....
  13. ncbi request reprint A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution
    Benny J Chen
    Department of Medicine and Immunology, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27705, USA
    Blood 99:364-71. 2002
    ..These results suggest that full-term fetal blood can engraft allogeneic hosts across the major histocompatibility barrier with slower hematopoietic engraftment and impaired immune reconstitution...
  14. ncbi request reprint Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model
    Benny J Chen
    Bone Marrow Transplantation Program, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC 27705, USA
    Transplantation 73:115-21. 2002
    ..PG490-88, a semisynthetic derivative of a novel compound PG490 (triptolide) purified from a Chinese herb (Tripterygium wilfordii Hook F), is effective in prevention of murine graft-versus-host disease (GVHD)...
  15. ncbi request reprint Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
    ....
  16. ncbi request reprint Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen
    D A Rizzieri
    Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC 27710, USA
    Blood 98:3486-8. 2001
    ..The patients are in remission and remain 100% donor as assessed by short tandem repeat analysis of the marrow 6 and 12 months following transplantation...
  17. pmc Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
    J Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Bone Marrow Transplant 47:700-5. 2012
    ....
  18. ncbi request reprint T-Cell recovery in adults and children following umbilical cord blood transplantation
    A K Klein
    Department of Medicine and the Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA. span.org
    Biol Blood Marrow Transplant 7:454-66. 2001
    ....
  19. ncbi request reprint Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease
    Benny J Chen
    Bone Marrow Transplantation Program, Department of Medicine, Human Vaccine Institute, Duke University Medical Center, 2400 Pratt St, Ste 1100, Box 3961, Durham, NC 27705, USA
    Blood 103:1534-41. 2004
    ..This novel technology may allow transfer of allogeneic recall antitumor and antimicrobial immunity without causing GVHD...
  20. doi request reprint Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity
    Garrett G Muramoto
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Stem Cells 28:523-34. 2010
    ..Pharmacologic inhibition of ALDH has therapeutic potential as a means to amplify ST-HSCs for transplantation purposes...
  21. pmc Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo
    Alice B Salter
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 113:2104-7. 2009
    ..These data demonstrate that allogeneic EPC infusions can augment hematopoiesis and suggest a relationship between BM microvascular recovery and hematopoietic reconstitution in vivo...
  22. pmc Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors
    D F Chen
    Clinical Transplantation Immunology Laboratory, Department of Pathology, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Bone Marrow Transplant 47:817-23. 2012
    ..These results suggest that the absence of appropriate HLA ligands in the recipient to donor iKIR may induce GVL without aGVHD in myeloid malignancy patients undergoing TCD-RIC transplants...
  23. ncbi request reprint Vascular endothelial cells produce soluble factors that mediate the recovery of human hematopoietic stem cells after radiation injury
    Garrett G Muramoto
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 12:530-40. 2006
    ....
  24. doi request reprint Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration
    M E Horwitz
    Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 47:1051-5. 2012
    ..In all, 15 out of 20 (75%) patients achieved the primary end point. In conclusion, the decision to administer plerixafor can be delayed until after the peak mobilization response to G-CSF has been fully assessed...
  25. ncbi request reprint Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
    D A Rizzieri
    Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
    J Clin Oncol 17:3064-74. 1999
    ..We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy...
  26. ncbi request reprint High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
    S J Horning
    Department of Medicine, Divisions of Bone Marrow Transplantation and Medical Oncology, Stanford University Medical Center, Stanford, CA, USA
    Blood 97:404-9. 2001
    ....
  27. ncbi request reprint Unrelated umbilical cord blood transplantation in adult patients
    Gwynn D Long
    Bone Marrow Transplantation Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 9:772-80. 2003
    ..Infection was the primary cause of death. These results suggest that unrelated umbilical cord blood transplantation is a viable option for adult patients and should be explored in patients with earlier-stage disease...
  28. doi request reprint Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy
    Christopher A Crout
    Duke University Medical Center, Department of Medicine, Division of Oncology and Stem Cell Transplantation, Adult Bone Marrow Transplantation Program, Durham, NC, USA
    Cancer Invest 28:654-60. 2010
    ..High responses were noted, though durable remissions were few, indicating non-traditional chemotherapy options are important to investigate in this illness...
  29. pmc Gene expression signatures that predict radiation exposure in mice and humans
    Holly K Dressman
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Med 4:e106. 2007
    ..The capacity to assess environmental inputs to biological phenotypes is limited by methods that can accurately and quantitatively measure these contributions. One such example can be seen in the context of exposure to ionizing radiation...
  30. ncbi request reprint Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation
    Benny J Chen
    Bone Marrow Transplantation Program, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA
    Blood 99:2235-40. 2002
    ....
  31. ncbi request reprint Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice
    Benny J Chen
    Departments of Medicine and Immunology, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27705, USA
    Exp Hematol 31:953-8. 2003
    ..To test in a murine model whether recombinant human growth hormone can promote immune recovery after allogeneic T-cell-depleted bone marrow transplantation...
  32. ncbi request reprint Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
    Cristina Gasparetto
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Cytokine 18:8-19. 2002
    ..In summary, administration of FL in combination with GM-CSF and G-CSF to patients with breast cancer can mobilize large numbers of immature DCs into PBSC leukapheresis collections...
  33. ncbi request reprint Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection
    B J Byrne
    Division of Stem Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 41:39-43. 2008
    ..Two patients are still in recovery phase less than 1 year from the second transplant. Long-term remission is possible and three patients are alive in complete remission...
  34. pmc Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture
    Rachid Safi
    Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710, USA
    Mol Endocrinol 23:188-201. 2009
    ..These data indicate that the RAR/RXR heterodimer is a critical regulator of human HSC differentiation, and pharmacological modulation of RXR signaling prevents the loss of human HSCs that otherwise occurs in short-term culture...
  35. pmc Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment
    J Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Bone Marrow Transplant 48:926-31. 2013
    ..This study suggests that use of CYA for GVHD prophylaxis increases the risk of PES following dual UCB transplantation...
  36. pmc Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells
    J M Palmer
    Division of Cellular Therapy, BMT Duke University Medical Center, Durham, NC, USA
    Bone Marrow Transplant 45:379-84. 2010
    ..These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin...
  37. ncbi request reprint Pathophysiologic mechanisms of acute graft-vs.-host disease
    J L Ferrara
    Department of Medicine, University of Michigan Medical School and University of Michigan Cancer Center, Ann Arbor 48109 0942, USA
    Biol Blood Marrow Transplant 5:347-56. 1999
    ..In this article, these mechanisms are reviewed and synthesized into a coherent conceptual framework, providing a state-of-the-art summary of the pathophysiology of acute GVHD...
  38. ncbi request reprint Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment
    Anand S Lagoo
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 130:1479-88. 2006
    ..Nonmyeloablative stem cell transplantation (NMSCT) is a mode of immunotherapy increasingly employed in treating hematologic, lymphoid, and solid tumors. Patients are monitored principally by molecular analysis of donor engraftment...
  39. ncbi request reprint Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Steven L McCune
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 43:1007-11. 2002
    ..Alemtuzumab is a monoclonal antibody that offers effective treatment for chemotherapy refractory CLL and PLL and is generally well tolerated in the outpatient setting...
  40. pmc Are there effective new strategies for the treatment of acute and chronic GvHD?
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University, 2400 Pratt Street, Suite 9011, Box 3961, Durham, NC 27710, USA
    Best Pract Res Clin Haematol 21:93-8. 2008
    ....
  41. doi request reprint Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 115:2922-9. 2009
    ..Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed...
  42. doi request reprint Unmanipulated or CD34 selected haplotype mismatched transplants
    Yubin Kang
    Division of Hematology, Oncology and Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Hematol 15:561-7. 2008
    ..This review summarizes recent investigations aimed at optimizing outcomes...
  43. doi request reprint "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma
    Cristina Gasparetto
    Department of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Biol Blood Marrow Transplant 16:70-7. 2010
    ..VMP did not negatively affect stem cell collection. Longer follow-up and prospective phase III trials are required to validate these initial observations...
  44. ncbi request reprint Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process
    Benny J Chen
    Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC 27705, USA
    Blood 99:3083-8. 2002
    ..These data suggest that PDP can selectively deplete host alloantigen-specific T cells for GVHD prevention and immune and antileukemia function preserve...
  45. pmc Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates
    Benny J Chen
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 5:e11056. 2010
    ..Our data demonstrate that rhGH promotes hematopoietic engraftment and immune recovery post the exposure of ionizing radiation and mitigates against the mortality from lethal irradiation even when administered after exposure...
  46. doi request reprint Iron overload and allogeneic hematopoietic stem-cell transplantation
    Junya Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC 27705, USA
    Expert Rev Hematol 4:71-80. 2011
    ..However, further research is needed to prove the direct relationship between iron overload and adverse outcomes, as well as to determine the effects of treatment for iron overload on outcomes of allogeneic stem-cell transplantation...
  47. pmc Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:56-61. 2011
    ..The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant...
  48. pmc Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles
    Sarah K Meadows
    Division of Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina, United States of America
    PLoS ONE 5:e11535. 2010
    ....
  49. doi request reprint Haploidentical transplantation for leukemia
    Junya Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Curr Oncol Rep 12:292-301. 2010
    ..Success of these new procedures will make haploidentical transplants safer and more effective, further broadening its appeal...
  50. ncbi request reprint Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation
    Matthew J Snyder
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg Pathol 28:794-800. 2004
    ..All three PTLDs arose 6 to 7 months after NMST and were rapidly fatal. The pathology of the PTLD in all cases was donor origin, EBV positive, diffuse large B-cell lymphoma...
  51. pmc Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells
    Heather A Himburg
    Division of Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina, USA
    Nat Med 16:475-82. 2010
    ..We identify the secreted growth factor pleiotrophin as a new regulator of both HSC expansion and regeneration...
  52. pmc Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation
    David A Rizzieri
    Duke University Medical Center, Department of Medicine, Division of Cellular Therapy, Durham, North Carloina, 27705, USA
    Biol Blood Marrow Transplant 16:1107-14. 2010
    ..Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery...
  53. ncbi request reprint Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors
    Liang Piu Koh
    Adult Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 13:1249-67. 2007
    ..Future challenges remain in determining the safest approach for haploidentical transplant to be performed with minimal risk of GVHD, whereas preserving effective graft-versus-leukemia activity and promoting prompt immune reconstitution...
  54. ncbi request reprint Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation
    Benny J Chen
    Bone Marrow Transplantation Program, Department of Medicine, Human Vaccine Institute, Duke University Medical Center, Box 3289, 250 Carl Building, Durham, NC 27710, USA
    Blood 103:4344-52. 2004
    ..Higher numbers of total thymocytes and signal joint T-cell receptor excision circles were observed in the higher dose stem cell recipients, suggesting that accelerated regeneration of T cells was due to enhanced thymopoiesis...
  55. ncbi request reprint Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 104:642-8. 2004
    ..These data demonstrate this radiopharmaceutical to be an encouraging agent for the treatment of lymphoma particularly if methods to protect the normal viscera are developed...
  56. ncbi request reprint Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
    David A Rizzieri
    Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA
    Cancer 100:2408-14. 2004
    ..The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL...
  57. ncbi request reprint Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis
    John P Chute
    Division of Cellular Therapy, Department of Internal Medicine, Duke University, Durham, North Carolina 27710, USA
    Stem Cells 24:1315-27. 2006
    ..These data demonstrate the potential of primary HUBECs as a reservoir for the discovery of novel secreted proteins that regulate human hematopoiesis...
  58. ncbi request reprint Non-pharmacologic approaches to graft-versus-host prevention
    Sam O Wanko
    Bone Marrow Transplant and Cellular Therapy, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Box 3961, Durham, NC 27710, USA
    Blood Rev 19:203-11. 2005
    ....
  59. pmc Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34
    Robert W Storms
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Box 3361, Durham, NC 27710, USA
    Blood 106:95-102. 2005
    ..The differential expression of ALDH may provide a means to explore normal and malignant processes associated with myeloid and lymphoid development...
  60. ncbi request reprint 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 9:183-8. 2003
    ..Approaches to minimize stomatitis and protect normal stem cells from the toxicity of 4HC may improve the tolerance and efficacy of this approach...
  61. ncbi request reprint Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia
    David A Rizzieri
    Duke University Medical Center, Division of Medical Oncology and Transplantation and the Duke Oncology Consortium, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:663-8. 2003
    ....
  62. pmc Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells
    John P Chute
    Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 103:11707-12. 2006
    ..Modulation of ALDH activity and retinoid signaling is a previously unrecognized and effective strategy to amplify human HSCs...
  63. pmc Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse
    Benny J Chen
    Division of Cellular Therapy Bone Marrow Transplantation, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 109:3115-23. 2007
    ..The abortive immune response, which was mediated by non-alloantigen-specific memory T cells in response to alloantigens, may explain why memory T cells from unprimed and non-alloantigen-primed donors could not induce GVHD...
  64. ncbi request reprint Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
    ..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype...
  65. pmc Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice
    John P Chute
    Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Blood 109:2365-72. 2007
    ..These data suggest that reestablishment of endothelial cell activity can improve the hematopoietic recovery and survival of irradiated mice...
  66. ncbi request reprint Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting
    N T Le
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC 27705, USA
    Cytotherapy 7:126-33. 2005
    ..Minimizing the threat of GvHD while maximizing the beneficial GvT effect would broaden the scope and effectiveness of alloSCT...
  67. ncbi request reprint Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
    C B Miller
    St Agnes HealthCare, Durham, NC, USA
    Bone Marrow Transplant 33:543-8. 2004
    ..Study results suggest that renal function improves and mortality declines when an LFAB is given to HSCT patients as initial therapy rather than as second-line therapy, the current practice...
  68. ncbi request reprint Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens
    Liang Piu Koh
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:1-22. 2004
    ..This review summarizes the available data on the use of UCB as an alternative source of hematopoietic stem cell transplantation in adult patients...
  69. pmc Gene expression signatures of radiation response are specific, durable and accurate in mice and humans
    Sarah K Meadows
    Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 3:e1912. 2008
    ..Previous work has demonstrated the potential for peripheral blood (PB) gene expression profiling for the detection of disease or environmental exposures...
  70. ncbi request reprint Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation
    Congxiao Liu
    The Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 12:335-45. 2006
    ..These results suggest that the T-cell receptor repertoire perturbations associated with acute GVHD are widely spread throughout the TCRBV families...
  71. ncbi request reprint Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation
    B D Alexander
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Transpl Infect Dis 8:13-20. 2006
    ..With only 1 of 40 subjects developing IFI while receiving treatment, the combination of fluconazole and inhaled ABLC warrants further study as antifungal prophylaxis following allogeneic HSCT...
  72. pmc Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review
    Liang Piu Koh
    Adult Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC, USA
    Blood Cells Mol Dis 40:20-4. 2008
    ..Future challenges remain in determining the safest approach for haploidentical transplant to be performed with minimal risk of GvHD, while preserving effective graft-versus-leukemia activity and promoting prompt immune reconstitution...
  73. pmc Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model
    Yubin Kang
    Divisions of Hematology, Oncology and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 5:e11316. 2010
    ..Our results indicate that AMD3100 provides a novel approach for enhancing hematological recovery following transplantation, and will likely benefit patients undergoing transplantation...
  74. ncbi request reprint Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid
    Sam O Wanko
    Department of Medicine, Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 12:949-53. 2006
    ..Although these historically lower DAH outcomes are intriguing, prospective studies are needed to confirm the role of aminocaproic acid in DAH occurring in the allogeneic transplantation setting...
  75. pmc Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation
    Ian Horkheimer
    Departments of Medicine, Duke University Medical Center, Durham, NC 2771, USA
    Blood 113:5330-9. 2009
    ..Collectively, these results may suggest effective immunotherapeutic strategies for treating cancer after stem cell transplantation...
  76. ncbi request reprint Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?
    Rajesh Bhagat
    Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 126:642-4. 2004
    ..We suggest that pulmonary sarcoidosis may develop following either autologous or allogeneic HSCT, and the prevalence may be 10-fold higher than that of the normal population...
  77. doi request reprint The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease
    Phuong L Doan
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Drugs 69:1339-50. 2009
    ..At present, more data are required before the addition of beclometasone dipropionate to systemic corticosteroids for the treatment of acute GVHD can be considered the standard of care...
  78. ncbi request reprint Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
    Laura J Johnston
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 11:47-55. 2005
    ..Given the significant toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be pursued in future cGVHD trials...
  79. ncbi request reprint High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes
    Monic J Stuart
    Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California, USA
    Biol Blood Marrow Transplant 8:666-73. 2002
    ..Our study presents long-term favorable results regarding the use of consolidative HDC with autologous hematopoietic support in previously untreated patients with high-risk primary breast cancer...
  80. ncbi request reprint A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
    Francis J Giles
    M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:559-65. 2004
    ..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
  81. ncbi request reprint T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil
    Murat O Arcasoy
    Am J Hematol 78:161-3. 2005
  82. pmc Radiologic and nuclear events: contingency planning for hematologists/oncologists
    David M Weinstock
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 111:5440-5. 2008
    ..Practitioners and institutions across the country are encouraged to become involved and participate in the planning...

Research Grants11

  1. Novel Approaches to Stem Cell Transplantation
    Nelson Chao; Fiscal Year: 2007
    ..These three aims are supported by two cores: an administrative and research coordination core and a biostatistics and data management core. The hope is to identify the most promising approaches for future studies. ..
  2. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2007
    ..abstract_text> ..
  3. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2006
    ..abstract_text> ..
  4. Non-Myeloablative Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2003
    ....
  5. CORD BLOOD TRANSPLANTATION IN ADULT RECIPIENTS
    Nelson Chao; Fiscal Year: 2001
    ..It is expected that upon completion of these studies, a prospective randomized study will be conducted comparing the source of unrelated donor hematopoietic cells. ..